U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Ad
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 61.02 -0.66 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.68 | 52 Week High | $77.12 | |||
| Open | $61.50 | 52 Week Low | $49.03 | |||
| Day High | $61.81 | P/E | 39.62 | |||
| Day Low | $61.02 | EPS | $1.54 | |||
| Volume | 1,565,908 | |||||
